Phase 3 N=616 Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC
Hepatic Neoplasm Malignant Recurrent
Primary: Recurrence-free Survival — 809.0; 751.0 Days — p=0.351
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=56 Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response
Essential Tremor · Tremor
Primary: Regions With fMRI Differences Between ET and Controls — 139; 93; 85; 74 Number of Activated Voxels
Phase 3 N=39 Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation
Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 12 Weeks Post Quit Date — 7 Participants
N/A N=35 Multiple CoolSculpting Treatment Study
Body Fat Disorder
Primary: Evaluation of Liver- Related Tests Over Time — 62.12; 63.88; 63.74; 62.06 units per liter (U/L)
N/A N=34 Psoriasis Microbiome and Phototherapy
Psoriasis
Primary: Cutaneous Microbiota Shannon's Alpha Diversity at Baseline — -0.05; 0.06; -0.06; 0.12 Shannon's index
Phase 2 N=132 A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Overall Survival (OS): Number of Events — 15; 58; 31 Participants with events — p=0.837
Phase 2 N=16 Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation
Male Hypogonadism
Primary: Mean T Cavg25 Following Meals Containing Various Amounts of Dietary Fat Compared to Normal Fat Diet — 6.38; 6.73; 6.88; 7.00 ng/dL — p=0.0025
Phase 4 N=49 Trial of Alvimopan in Major Spine Surgery
Constipation
Primary: Time to First Bowel Movement — 50; 64 hours
N/A N=44 Dispensing Study for a New Study Lens
Myopia
Primary: Distance Visual Acuity (VA) - High Illumination — -0.10; -0.11; -0.15; -0.17 logMAR
N/A N=225 Marathon and Enduron Polyethylene at Long-Term Follow-up
Osteoarthritis · Arthritis · Joint Diseases
Primary: Percentage of Hips Surviving at 15 Years — 100; 86 percentage of hips surviving at 15-years — p=<0.001
Phase 2 N=14 Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
N/A N=626 Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI
Post Procedural Myocardial Infarction
Primary: Peri-Procedural Myocardial Injury — 23; 29 Participants
N/A N=50 Effect of Obesity on Immune Response to Pneumovax 23
Obesity
Primary: Anti-pneumococcal Antibodies Between the Groups — 34.1; 19.8 titer
Phase 2 N=77 Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Parkinson Disease
Primary: Safety Adverse Events — 0; 0; 0; 0 participants
N/A N=272 Contraceptive Awareness and Reproductive Education
Pregnancy · Sexually Transmitted Infections
Primary: Number of Participants With Continuous Use of Highly Effective Contraceptives Over 9 Months. — 39; 29 Participants — p=>.05